

Global Cell and Gene Therapy Manufacturing QC Market: Focus on Products and Services, Process, Analytical Method, Technology, 17 Countries' Data and Competitive Landscape - Analysis and Forecast, 2020-2030

<https://marketpublishers.com/r/G0512CB7D2EFEN.html>

Date: March 2021

Pages: 238

Price: US\$ 5,000.00 (Single User License)

ID: G0512CB7D2EFEN

Abstracts

Hard copy option is available on any of the options above at an additional charge of \$500. Please email us at order@marketpublishers.com with your request.

Market Report Coverage - Cell and Gene Therapy Manufacturing QC

Market Segmentation

Product – Services and Products (Kits and Assays, Instruments, Reagents, and Software)

Process – Starting Material Preparation, Upstream Processing, and Downstream Processing

Analytical Methods – Safety Testing, Purity Testing, Potency Testing, Identity Testing, and Stability Testing

Technology – Polymerase Chain Reaction (PCR), Flow Cytometry, Limulus Amebocyte Lysate (LAL), Enzyme-Linked Immunosorbent Assay (ELISA), Chromatography, Mass Spectrometry, Western Blotting, Next-Generation Sequencing (NGS), and Electrophoresis, among others

Regional Segmentation

North America – U.S., and Canada

Europe – Germany, U.K., France, Italy, Spain, Netherlands, Russia, and Rest-of-Europe

Asia-Pacific – China, Japan, India, Australia, South Korea, Singapore, and Rest-of-Asia-Pacific

Latin America – Brazil, Mexico, and Rest-of-Latin America

Rest-of-the-World

Growth Drivers

Increasing Prevalence of Cancer and Chronic Diseases

Rising Number of Clinical Trials

Steady Investment and Consolidation in the Cell and Gene Therapy Market

Favorable Regulatory Environment

Market Challenges

Lack of Reliable Vector Production for Cell and Gene Therapy

Lack of Therapy Specific Assays

Market Opportunities

Drug Approvals and Strong Pipeline of Cell and Gene Therapies

Multiple Investments in Expansion of cGMP Units

Key Companies Profiled

bioMérieux SA, Bio-Techne Corporation, Catalent, Inc., Charles River Laboratories International, Inc., Eurofins Scientific S.E., F. Hoffmann-La Roche Ltd., Intertek Group plc, Lonza Group AG, Merck KGaA, Sartorius AG, SGS S.A, Thermo Fisher Scientific Inc., WuXi AppTec, Sitemic Scotland Limited, and Vigene Biosciences, Inc.

Key Questions Answered in this Report:

What are the major market drivers, challenges, and opportunities and their respective impacts in the global cell and gene therapy manufacturing QC market?

What is the potential impact of advancement in QC in the contract development and manufacturing organization among the cell and gene therapy innovators?

What is the current market demand along with future expected demand for the global cell and gene therapy manufacturing QC market?

What are the key regulatory hurdles for industry players looking to enter this highly dynamic market?

What are the key development strategies that are implemented by the major players in order to sustain the competitive market?

How is each of the following segments of the market expected to grow during the forecast period from 2020 to 2030:

product

process

analytical method

technology

region, namely, North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World (RoW)

Who are the leading players with significant offerings to the global cell and gene therapy manufacturing QC market? What is the expected market dominance for each of these leading players?

Which emerging companies are anticipated to be highly disruptive in the future, and what are their key strategies for sustainable growth in the global cell and gene therapy manufacturing QC market?

How is automation expected to change scale up challenges in the market?

What is the cost of QC vs production cost for cell and gene therapies and what strategies are leading players undertaking in order to maximize profits?

Market Overview

Our healthcare experts have found the manufacturing QC for cell and gene therapy to be one of the most rapidly evolving and dynamic markets and the global market for cell and gene therapy manufacturing QC is predicted to grow at a CAGR of 22.80% over the forecast period of 2020-2030. The market is driven by certain factors, which include increasing prevalence of cancer and chronic diseases, rising number of clinical trials for cell and gene therapy, steady investment and consolidation in the cell and gene therapy market, and favorable regulatory environment are fueling the growth of the global cell and gene therapy manufacturing QC market.

Manufacturing, being a hallmark of enabling advanced therapies to be disseminated across the patient population, is a consistent driving force behind the growth of overall adoption of innovative therapies. Quality control is a critical aspect of manufacturing, particularly considering advanced therapies such as cell and gene therapies. Profit generation aside, the cost of therapies can primarily be controlled through optimizing manufacturing costs. This will also require the optimization of cost in the underlying factors, including quality control. While a majority of regulators are currently mandating rapid testing technologies, CDMO juggernauts have already begun offering services and products based on advanced technologies such as NGS and PCR. Not only as an attractive promoting tool to gather more cell and gene innovators, but these market leaders are also driving consolidation within the industry by acquiring smaller companies offering unique products and services. As a result, there is tremendous dynamicity in the market, propelling overall access to cell and gene therapies even in smaller developing countries.

Within the research report, the market is segmented on the basis of products, processes, analytical methods, technologies, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

Rapid technological developments and their simultaneous adoption among major companies have made the global cell and gene therapy manufacturing QC market one of the most lucrative opportunities for major companies within the precision therapeutics biosphere. With both market juggernauts and emerging companies playing a significant role in the market, this industry is rapidly evolving into a highly rewarding market for manufacturers and end users. Although mostly based in Europe, market leaders such as Merck KGaA and Lonza Group AG, have been at the forefront in enabling cell and gene manufacturing capabilities across North America and the Asia-Pacific regions.

On the basis of region, North America holds the largest share of the cell and gene therapy manufacturing QC market due to a high number of active cell and gene therapy clinical trials, massive government funding, expansion activities by major companies, and an overall high adoption rate for advancing therapies. Apart from this, Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period, 2020-2030.

Contents

Executive Summary

1 PRODUCT DEFINITION AND MARKET SCOPE

1.1 Inclusion and Exclusion

1.2 Scope of Work

1.3 Key Questions Answered in the Report

2 RESEARCH METHODOLOGY

2.1 Primary Data Sources

2.2 Secondary Data Sources

2.3 Market Estimation Model

2.4 Criteria for Company Profiling

3 MARKET OVERVIEW

3.1 Clinical Importance of Cell and Gene Therapies

3.2 Cell and Gene Therapy Manufacturing QC: Industry Overview

3.3 Market Footprint

3.4 Impact of COVID-19

4 MARKET DYNAMICS

4.1 Impact Analysis

4.2 Market Drivers

4.2.1 Increasing Prevalence of Cancer and Chronic Diseases

4.2.2 Rising Number of Clinical Trials

4.2.3 Steady Investment and Consolidation in the Cell and Gene Therapy Market

4.2.4 Favorable Regulatory Environment

4.3 Market Restraints

4.3.1 Lack of Reliable Vector Production for Cell and Gene Therapy

4.3.2 Lack of Therapy Specific Assays

4.4 Opportunities

4.4.1 Drug Approvals and Strong Pipeline of Cell and Gene Therapies

4.4.2 Multiple Investments in Expansion of cGMP Units

5 INDUSTRY INSIGHTS

5.1 Role of Regulatory Bodies and Consortium in Cell and Gene Therapy

5.1.1 Regulatory Challenges

5.1.2 Successful Regulatory Strategies

5.2 Regulatory Framework

5.2.1 Chemistry, Manufacturing, and Control (CMC) Requirements by the FDA

5.2.1.1 Product Testing

5.2.1.1.1 Microbial Testing

5.2.1.1.2 Identity

5.2.1.1.3 Purity

5.2.1.1.4 Potency

5.2.1.1.5 Viability

5.2.1.1.6 Cell Number/Dose

5.2.2 Quality Aspects of Cell and Gene Therapy Products by the EMA

5.2.2.1 Characterization

5.2.2.1.1 Identity Testing

5.2.2.1.2 Purity Testing

5.2.2.1.3 Potency Testing

5.2.2.1.4 Release Criteria

5.2.3 Quality Control Requirements for Cell and Gene Therapies in China

5.2.3.1 CAR-T Cell Therapy

5.2.3.2 Gene Therapy

5.3 Cost Analysis for Cell and Gene Therapy QC

6 GLOBAL CELL AND GENE THERAPY MANUFACTURING QC MARKET: COMPETITIVE INSIGHTS

6.1 Overview

6.2 Synergistic Activities

6.3 Expansion Activities

6.4 Product and Service Launches

6.5 Acquisitions

6.6 Other Developments

6.7 Market Share Analysis, 2019-2020

6.8 Growth Share Analysis

6.8.1 Growth Share Analysis (by Company)

6.8.2 Growth Share Analysis (by Technology)

6.8.3 Growth Share Analysis (by Analytical Method)

7 GLOBAL CELL AND GENE THERAPY MANUFACTURING QC MARKET (BY PRODUCT AND SERVICE), \$MILLION, 2019-2030

7.1 Overview

7.2 Service

7.3 Product

8 GLOBAL CELL AND GENE THERAPY MANUFACTURING QC MARKET (BY PROCESS), \$MILLION, 2019-2030

8.1 Overview

8.2 Starting Material Preparation

8.3 Upstream Processing

8.4 Downstream Processing

9 GLOBAL CELL AND GENE THERAPY MANUFACTURING QC MARKET (BY ANALYTICAL METHOD), \$MILLION, 2019-2030

9.1 Overview

9.2 Safety Testing

9.3 Purity Testing

9.4 Potency Testing

9.5 Identity Testing

9.6 Stability Testing

10 GLOBAL CELL AND GENE THERAPY MANUFACTURING QC MARKET (BY TECHNOLOGY), \$MILLION, 2019-2030

10.1 Overview

10.2 Polymerase Chain Reaction

10.3 Flow Cytometry

10.4 Limulus Amebocyte Lysate (LAL)

10.5 Enzyme-Linked Immunosorbent Assay (ELISA)

10.6 Chromatography

10.7 Mass Spectrometry

10.8 Western Blotting

10.9 Next-Generation Sequencing

10.1 Electrophoresis

10.11 Other Technologies

11 GLOBAL CELL AND GENE THERAPY MANUFACTURING QC MARKET (BY REGION), \$MILLION, 2019-2030

11.1 Overview

11.2 North America

11.2.1 U.S.

11.2.2 Canada

11.3 Europe

11.3.1 Germany

11.3.2 U.K.

11.3.3 France

11.3.4 Italy

11.3.5 Spain

11.3.6 Netherlands

11.3.7 Russia

11.3.8 Rest-of-Europe

11.4 Asia-Pacific

11.4.1 China

11.4.2 Japan

11.4.3 South Korea

11.4.4 Australia

11.4.5 India

11.4.6 Singapore

11.4.7 Rest-of-Asia-Pacific

11.5 Latin America

11.5.1 Brazil

11.5.2 Mexico

11.5.3 Rest-of-Latin America

11.6 Rest-of-the-World (RoW)

12 COMPANY PROFILES

12.1 Overview

12.2 bioMérieux SA

12.2.1 Company Overview

12.2.2 Role of bioMérieux SA in Global Cell and Gene Therapy Manufacturing QC Market

- 12.2.3 Financials
- 12.2.4 Key Insights About Financial Health of the Company
- 12.2.5 SWOT Analysis
- 12.3 Bio-Techne Corporation
 - 12.3.1 Company Overview
 - 12.3.2 Role of Bio-Techne Corporation in Global Cell and Gene Therapy
- Manufacturing QC Market
 - 12.3.3 Financials
 - 12.3.4 Key Insights About Financial Health of the Company
 - 12.3.5 SWOT Analysis
- 12.4 Catalent, Inc.
 - 12.4.1 Company Overview
 - 12.4.2 Role of Catalent, Inc. in Global Cell and Gene Therapy Manufacturing QC Market
 - 12.4.3 Financials
 - 12.4.4 Key Insights About Financial Health of the Company
 - 12.4.5 SWOT Analysis
- 12.5 Charles River Laboratories International Inc.
 - 12.5.1 Company Overview
 - 12.5.2 Role of Charles River Laboratories International Inc. in the Global Cell and Gene Therapy Manufacturing QC Market
 - 12.5.3 Financials
 - 12.5.4 SWOT Analysis
- 12.6 Eurofins Scientific SE
 - 12.6.1 Company Overview
 - 12.6.2 Role of Eurofins Scientific SE in the Global Cell and Gene Therapy Manufacturing QC Market
 - 12.6.3 Financials
 - 12.6.4 SWOT Analysis
- 12.7 F. Hoffmann-La Roche Ltd
 - 12.7.1 Company Overview
 - 12.7.2 Role of F. Hoffmann-La Roche Ltd. in the Global Cell and Gene Therapy Manufacturing QC Market
 - 12.7.3 Financials
 - 12.7.4 Key Insights About Financial Health of the Company
 - 12.7.5 SWOT Analysis
- 12.8 Intertek Group plc
 - 12.8.1 Company Overview
 - 12.8.2 Role of Intertek Group plc in the Global Cell and Gene Therapy Manufacturing

QC Market

12.8.3 Financials

12.8.4 Key Insights About Financial Health of the Company

12.8.5 SWOT Analysis

12.9 Lonza Group AG

12.9.1 Company Overview

12.9.2 Role of Lonza Group AG in the Global Cell and Gene Therapy Manufacturing

QC Market

12.9.3 Financials

12.9.4 SWOT Analysis

12.1 Merck KGaA

12.10.1 Company Overview

12.10.2 Role of Merck KGaA in the Global Cell and Gene Therapy Manufacturing QC

Market

12.10.3 Financials

12.10.4 Key Insights About Financial Health of the Company

12.10.5 SWOT Analysis

12.11 Sartorius AG

12.11.1 Company Overview

12.11.2 Role of Sartorius AG in the Global Cell and Gene Therapy Manufacturing QC

Market

12.11.3 Financials

12.11.4 Key Insights About Financial Health of the Company

12.11.5 SWOT Analysis

12.12 SGS S.A.

12.12.1 Company Overview

12.12.2 Role of SGS S.A. in the Global Cell and Gene Therapy Manufacturing QC

Market

12.12.3 Financials

12.12.4 SWOT Analysis

12.13 Sismic Scotland Limited

12.13.1 Company Overview

12.13.2 Role of Sismic Scotland Limited in Global Cell and Gene Therapy

Manufacturing QC Market

12.13.3 SWOT Analysis

12.14 Thermo Fisher Scientific Inc.

12.14.1 Company Overview

12.14.2 Role of Thermo Fisher Scientific Inc. in the Global Cell and Gene Therapy

Manufacturing QC Market

12.14.3 Financials

12.14.4 Key Insights About Financial Health of the Company

12.14.5 SWOT Analysis

12.15 Vigene Biosciences, Inc.

12.15.1 Company Overview

12.15.2 Role of Vigene Biosciences, Inc. in Global Cell and Gene Therapy

Manufacturing QC Market

12.15.3 SWOT Analysis

12.16 WuXi AppTec

12.16.1 Company Overview

12.16.2 Role of WuXi AppTec in Global Cell and Gene Therapy Manufacturing QC

Market

12.16.3 Financials

12.16.4 SWOT Analysis

List Of Tables

LIST OF TABLES

Table 3.1: Key Products of Cell and Gene Therapy Market

Table 4.1: Impact Analysis

Table 4.2: Key Cell and Gene Therapies with FDA Expedited Review

Table 5.1: Product Class Inclusions in EU and U.S. Regulatory Pathway

Table 7.1: List of Key Services

Table 7.2: List of Key Products Offered

Table 9.1: Key Safety Testing Offerings

Table 9.2: Key Purity Testing Offerings

Table 9.3: Key Potency Testing Offerings

Table 9.4: Key Identity Testing Offerings

Table 9.5: Key Stability Testing Offerings

Table 10.1: Key PCR-Based Offerings

Table 10.2: Key Flow Cytometry-Based Offerings

Table 10.3: Key LAL-Based Offerings

Table 10.4: Key ELISA-Based Offerings

Table 10.5: Key Chromatography-Based Offerings

Table 10.6: Key Mass Spectrometry-Based Offerings

Table 10.7: Key Western Blotting-Based Offerings

Table 10.8: Key NGS-Based Offerings

Table 10.9: Key Electrophoresis-Based Offerings

List Of Figures

LIST OF FIGURES

Figure 1: Global Clinical Landscape for Regenerative Medicine, 2019

Figure 2: Impact Analysis on the Global Cell and Gene Therapy Manufacturing QC Market

Figure 3: Global Cell and Gene Therapy Manufacturing QC Market (by Product and Service), \$Million, 2019 and 2030

Figure 4: Global Cell and Gene Therapy Manufacturing QC Market (by Process), \$Million, 2019 and 2030

Figure 5: Global Cell and Gene Therapy Manufacturing QC Market (by Analytical Method), \$Million, 2019 and 2030

Figure 6: Global Cell and Gene Therapy Manufacturing QC Market (by Technology), \$Million, 2019 and 2030

Figure 7: Global Cell and Gene Therapy Manufacturing QC Market (by Region), Market Snapshot

Figure 1.1: Global Cell and Gene Therapy Manufacturing QC Market Segmentation
Primary Research Methodology

Figure 2.1: Bottom-Up Approach (Segment-Wise Analysis)

Figure 2.2: Top-Down Approach (Segment-Wise Analysis)

Figure 3.1: Clinical Trials by Therapeutic Category, Cell and Gene Therapy, 2019

Figure 3.2: Global Cell and Gene Therapy Manufacturing QC Market, \$Million, 2019-2030

Figure 3.3: Impact of COVID-19 on Global Cell and Gene Therapy Manufacturing QC Market, \$Million, 2019-2030

Figure 4.1: Number of Clinical Trials for ATMP (by Phase), 2019

Figure 5.1: Cost of Manufacturing Cell Therapies

Figure 6.1: Share of Key Developments and Strategies, January 2018-Januray 2021

Figure 6.2: Synergistic Activities Share (by Company), January 2018-January 2021

Figure 6.3: Expansion Activities Share (by Company), January 2018-January 2021

Figure 6.4: Product and Services Launches Share (by Company), January 2018-January 2021

Figure 6.5: Product and Services Launches Share (by Company), January 2018-January 2021

Figure 6.6: Market Share Analysis for Global Cell and Gene Therapy Manufacturing QC Market, 2019 and 2020

Figure 6.7: Growth Share Analysis for Global Cell and Gene Therapy Manufacturing QC Market (by Company), 2020

Figure 6.8: Growth Share Analysis for Global Cell and Gene Therapy Manufacturing QC Market (by Technology), 2019-2030

Figure 6.9: Growth Share Analysis for Global Cell and Gene Therapy Manufacturing QC Market (by Analytical Method), 2019-2030

Figure 7.1: Global Cell and Gene Therapy Manufacturing QC Market (by Product and Service), \$Million, 2019 and 2030

Figure 7.2: Global Cell and Gene Therapy Manufacturing QC Market (by Service), \$Million, 2019-2030

Figure 7.3: Global Cell and Gene Therapy Manufacturing QC Market (by Product), \$Million, 2019-2030

Figure 7.4: Global Cell and Gene Therapy Manufacturing QC Market (by Product), \$Million, 2019 and 2030

Figure 8.1: Global Cell and Gene Therapy Manufacturing QC Market (by Process), \$Million, 2019 and 2030

Figure 8.2: Global Cell and Gene Therapy Manufacturing QC Market (by Starting Material Preparation), \$Million, 2019-2030

Figure 8.3: Global Cell and Gene Therapy Manufacturing QC Market (by Upstream Processing), \$Million, 2019-2030

Figure 8.4: Global Cell and Gene Therapy Manufacturing QC Market (by Downstream Processing), \$Million, 2019-2030

Figure 9.1: Product Characterization Tests for Cell and Gene Therapy Manufacturing

Figure 9.2: Global Cell and Gene Therapy Manufacturing QC Market (by Analytical Method), \$Million, 2019 and 2030

Figure 9.3: Global Cell and Gene Therapy Manufacturing QC Market (by Safety Testing), \$Million, 2019-2030

Figure 9.4: Global Cell and Gene Therapy Manufacturing QC Market (by Safety Testing Type), \$Million, 2019 and 2030

Figure 9.5: Global Cell and Gene Therapy Manufacturing QC Market (by Purity Testing), \$Million, 2019-2030

Figure 9.6: Global Cell and Gene Therapy Manufacturing QC Market (by Purity Testing Type), \$Million, 2019 and 2030

Figure 9.7: Global Cell and Gene Therapy Manufacturing QC Market (by Potency Testing), \$Million, 2019-2030

Figure 9.8: Global Cell and Gene Therapy Manufacturing QC Market (by Potency Testing Type), \$Million, 2019 and 2030

Figure 9.9: Global Cell and Gene Therapy Manufacturing QC Market (by Identity Testing), \$Million, 2019-2030

Figure 9.10: Global Cell and Gene Therapy Manufacturing QC Market (by Stability Testing), \$Million, 2019-2030

Figure 9.11: Global Cell and Gene Therapy Manufacturing QC Market (by Stability Testing Type), \$Million, 2019 and 2030

Figure 10.1: Global Cell and Gene Therapy Manufacturing QC Market (by Technology), \$Million, 2019 and 2030

Figure 10.2: Global Cell and Gene Therapy Manufacturing QC Market (PCR), \$Million, 2019-2030

Figure 10.3: Global Cell and Gene Therapy Manufacturing QC Market (Flow Cytometry), \$Million, 2019-2030

Figure 10.4: Global Cell and Gene Therapy Manufacturing QC Market (LAL), \$Million, 2019-2030

Figure 10.5: Global Cell and Gene Therapy Manufacturing QC Market (ELISA), \$Million, 2019-2030

Figure 10.6: Global Cell and Gene Therapy Manufacturing QC Market (Chromatography), \$Million, 2019-2030

Figure 10.7: Global Cell and Gene Therapy Manufacturing QC Market (Mass Spectrometry), \$Million, 2019-2030

Figure 10.8: Global Cell and Gene Therapy Manufacturing QC Market (Western Blotting), \$Million, 2019-2030

Figure 10.9: Global Cell and Gene Therapy Manufacturing QC Market (NGS), \$Million, 2019-2030

Figure 10.10: Global Cell and Gene Therapy Manufacturing QC Market (Electrophoresis), \$Million, 2019-2030

Figure 10.11: Global Cell and Gene Therapy Manufacturing QC Market (Other Technologies), \$Million, 2019-2030

Figure 11.1: Global Cell and Gene Therapy Manufacturing QC Market (by Region), Market Snapshot

Figure 11.2: North America: Market Dynamics

Figure 11.3: North America Cell and Gene Therapy Manufacturing QC Market, \$Million, 2019-2030

Figure 11.4: North America Cell and Gene Therapy Manufacturing QC Market (by Country), \$Million, 2019 vs. 2030

Figure 11.5: U.S. Cell and Gene Therapy Manufacturing QC Market, \$Million, 2019-2030

Figure 11.6: Canada Cell and Gene Therapy Manufacturing QC Market, \$Million, 2019-2030

Figure 11.7: Europe: Market Dynamics

Figure 11.8: Europe Cell and Gene Therapy Manufacturing QC Market, \$Million, 2019-2030

Figure 11.9: Europe Cell and Gene Therapy Manufacturing QC Market (by Country),

\$Million, 2019 vs. 2030

Figure 11.10: Germany Cell and Gene Therapy Manufacturing QC Market, \$Million, 2019-2030

Figure 11.11: U.K. Cell and Gene Therapy Manufacturing QC Market, \$Million, 2019-2030

Figure 11.12: France Cell and Gene Therapy Manufacturing QC Market, \$Million, 2019-2030

Figure 11.13: Italy Cell and Gene Therapy Manufacturing QC Market, \$Million, 2019-2030

Figure 11.14: Spain Cell and Gene Therapy Manufacturing QC Market, \$Million, 2019-2030

Figure 11.15: Netherlands Cell and Gene Therapy Manufacturing QC Market, \$Million, 2019-2030

Figure 11.16: Russia Cell and Gene Therapy Manufacturing QC Market, \$Million, 2019-2030

Figure 11.17: Rest-of-Europe Cell and Gene Therapy Manufacturing QC Market, \$Million, 2019-2030

Figure 11.18: Asia-Pacific: Market Dynamics

Figure 11.19: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market, \$Million, 2019-2030

Figure 11.20: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Country), \$Million, 2019 vs. 2030

Figure 11.21: China Cell and Gene Therapy Manufacturing QC Market, \$Million, 2019-2030

Figure 11.22: Japan Cell and Gene Therapy Manufacturing QC Market, \$Million, 2019-2030

Figure 11.23: South Korea Cell and Gene Therapy Manufacturing QC Market, \$Million, 2019-2030

Figure 11.24: Australia Cell and Gene Therapy Manufacturing QC Market, \$Million, 2019-2030

Figure 11.25: Italy Cell and Gene Therapy Manufacturing QC Market, \$Million, 2019-2030

Figure 11.26: Singapore Cell and Gene Therapy Manufacturing QC Market, \$Million, 2019-2030

Figure 11.27: Rest-of-Europe Cell and Gene Therapy Manufacturing QC Market, \$Million, 2019-2030

Figure 11.28: Latin America: Market Dynamics

Figure 11.29: Latin America Cell and Gene Therapy Manufacturing QC Market, \$Million, 2019-2030

Figure 11.30: Latin America Cell and Gene Therapy Manufacturing QC Market (by Country), \$Million, 2019 vs. 2030

Figure 11.31: Brazil Cell and Gene Therapy Manufacturing QC Market, \$Million, 2019-2030

Figure 11.32: Mexico Cell and Gene Therapy Manufacturing QC Market, \$Million, 2019-2030

Figure 11.33: Rest-of-Latin America Cell and Gene Therapy Manufacturing QC Market, \$Million, 2019-2030

Figure 11.34: Rest-of-the-World Cell and Gene Therapy Manufacturing QC Market, \$Million, 2019-2030

Figure 12.1: Total Number of Companies Profiled

Figure 12.2: bioMérieux SA: Overall Product Portfolio

Figure 12.3: bioMérieux SA: Overall Financials, 2017-2019

Figure 12.4: bioMérieux SA: Revenue (by Segment), 2017-2019

Figure 12.5: bioMérieux SA: Revenue (by Region), 2017-2019

Figure 12.6: bioMérieux SA: R&D Expenditure, 2017-2019

Figure 12.7: bioMérieux SA: SWOT Analysis

Figure 12.8: Bio-Techne Corporation: Overall Product Portfolio

Figure 12.9: Bio-Techne Corporation: Overall Financials, 2018-2020

Figure 12.10: Bio-Techne Corporation: Revenue (by Segment), 2018-2020

Figure 12.11: Bio-Techne Corporation: Revenue (by Region), 2018-2020

Figure 12.12: Bio-Techne Corporation: R&D Expenditure, 2018-2020

Figure 12.13: Bio-Techne Corporation: SWOT Analysis

Figure 12.14: Catalent, Inc.: Overall Product Portfolio

Figure 12.15: Catalent, Inc.: Overall Financials, 2018-2020

Figure 12.16: Catalent, Inc.: Revenue (by Segment), 2018-2020

Figure 12.17: Catalent, Inc.: Revenue (by Region), 2018-2020

Figure 12.18: Catalent, Inc.: R&D Expenditure, 2018-2020

Figure 12.19: Catalent, Inc.: SWOT Analysis

Figure 12.20: Charles River Laboratories International Inc.: Overall Service Portfolio

Figure 12.21: Charles River Laboratories International Inc.: Overall Financials, 2017-2019

Figure 12.22: Charles River Laboratories International Inc.: Revenue (by Segment), 2017-2019

Figure 12.23: Charles River Laboratories International Inc.: Revenue (by Region), 2017-2019

Figure 12.24: Charles River Laboratories International Inc.: SWOT Analysis

Figure 12.25: Eurofins Scientific SE: Service Portfolio

Figure 12.26: Eurofins Scientific SE: Overall Financials, 2017-2019

- Figure 12.27: Eurofins Scientific SE: Revenue (by Segment), 2018-2019
- Figure 12.28: Eurofins Scientific SE: Revenue (by Region), 2017-2019
- Figure 12.29: Eurofins Scientific SE.: SWOT Analysis
- Figure 12.30: F. Hoffmann-La Roche Ltd.: Overall Product Portfolio
- Figure 12.31: F. Hoffmann-La Roche Ltd.: Overall Financials, 2018-2020
- Figure 12.32: F. Hoffmann-La Roche Ltd.: Revenue (by Segment), 2018-2020
- Figure 12.33: F. Hoffmann-La Roche Ltd.: Revenue (by Diagnostics), 2018-2020
- Figure 12.34: F. Hoffmann-La Roche Ltd.: Revenue (by Region), 2018-2020
- Figure 12.35: F. Hoffmann-La Roche Ltd.: R&D Expenditure, 2018-2020
- Figure 12.36: F. Hoffmann-La Roche Ltd.: SWOT Analysis
- Figure 12.37: Intertek Group plc: Overall Product Portfolio
- Figure 12.38: Intertek Group plc: Overall Financials, 2017-2019
- Figure 12.39: Intertek Group plc: Revenue (by Segment), 2017-2019
- Figure 12.40: Intertek Group plc: Revenue (by Region), 2017-2019
- Figure 12.41: Intertek Group plc: R&D Expenditure, 2017-2019
- Figure 12.42: Intertek Group plc: SWOT Analysis
- Figure 12.43: Lonza Group AG: Overall Product Portfolio
- Figure 12.44: Lonza Group AG: Overall Financials, 2018-2020
- Figure 12.45: Lonza Group AG: Revenue (by Segment), 2018-2020
- Figure 12.46: Lonza Group AG: Revenue (by Region), 2018-2020
- Figure 12.47: Lonza AG: SWOT Analysis
- Figure 12.48: Merck KGaA: Overall Product Portfolio
- Figure 12.49: Merck KGaA: Overall Financials, 2017-2019
- Figure 12.50: Merck KGaA: Revenue (by Segment), 2017-2019
- Figure 12.51: Merck KGaA: Revenue (by Region), 2017-2019
- Figure 12.52: Merck KGaA: R&D Expenditure, 2017-2019
- Figure 12.53: Merck KGaA: SWOT Analysis
- Figure 12.54: Sartorius AG: Overall Product Portfolio
- Figure 12.55: Sartorius AG: Overall Financials, 2017-2019
- Figure 12.56: Sartorius AG: Revenue (by Segment), 2017-2019
- Figure 12.57: Sartorius AG: Revenue (by Region), 2017-2019
- Figure 12.58: Sartorius AG: R&D Expenditure, 2017-2019
- Figure 12.59: Sartorius AG: SWOT Analysis
- Figure 12.60: SGS S.A.: Overall Product Portfolio
- Figure 12.61: SGS S.A.: Overall Financials, 2018-2020
- Figure 12.62: SGS S.A.: Revenue (by Segment), 2018-2020
- Figure 12.63: SGS S.A.: Revenue (by Region), 2018-2020
- Figure 12.64: SGS S.A.: SWOT Analysis
- Figure 12.65: Sismic Scotland Limited: Portfolio

- Figure 12.66: Sismic Scotland Limited: SWOT Analysis
- Figure 12.67: Thermo Fisher Scientific Inc.: Product Portfolio
- Figure 12.68: Thermo Fisher Scientific Inc.: Overall Financials: 2017-2019
- Figure 12.69: Thermo Fisher Scientific Inc.: Sales (by Segment): 2017-2020
- Figure 12.70: Thermo Fisher Scientific Inc.: Revenue (by Region), 2017-2019
- Figure 12.71: Thermo Fisher Scientific Inc.: R&D Expenditure, 2017-2019
- Figure 12.72: Thermo Fisher Scientific Inc.: SWOT Analysis
- Figure 12.73: Vigene Biosciences, Inc.: Portfolio
- Figure 12.74: Vigene Biosciences, Inc.: SWOT Analysis
- Figure 12.75: WuXi AppTec: Product Portfolio
- Figure 12.76: WuXi AppTec: Overall Financials, 2017-2019
- Figure 12.77: WuXi AppTec: Sales (by Segment), 2017-2019
- Figure 12.78: WuXi AppTec: Revenue (by Region), 2017-2019
- Figure 12.79: WuXi AppTec: SWOT Analysis

I would like to order

Product name: Global Cell and Gene Therapy Manufacturing QC Market: Focus on Products and Services, Process, Analytical Method, Technology, 17 Countries' Data and Competitive Landscape - Analysis and Forecast, 2020-2030

Product link: <https://marketpublishers.com/r/G0512CB7D2EFEN.html>

Price: US\$ 5,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G0512CB7D2EFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970